Compare TBPH & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | AIV |
|---|---|---|
| Founded | 2013 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 837.1M |
| IPO Year | 2013 | 1996 |
| Metric | TBPH | AIV |
|---|---|---|
| Price | $16.77 | $4.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $18.40 | $10.00 |
| AVG Volume (30 Days) | 402.7K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 87.00% |
| EPS Growth | 279.13 | ★ 616.00 |
| EPS | 2.06 | ★ 3.87 |
| Revenue | $15,386,000.00 | ★ $138,486,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.15 | ★ $1.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.33 | $3.94 |
| 52 Week High | $21.03 | $8.87 |
| Indicator | TBPH | AIV |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 50.39 |
| Support Level | $13.41 | $4.03 |
| Resistance Level | $17.24 | $4.28 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 57.01 | 85.37 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.